December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Smallpox Tops List of Bioterror Agents
September 1st 2003San Francisco - As the international situation has become more complicated, dermatologists have realized that they may need to diagnose and respond to individuals who have been infected by a microbial agent of bioterrorism. Among the several viral agents that could be so used, smallpox has caused the greatest concern, according to Scott A. Norton, M.D., M.P.H., M.Sc.
Tough Topicals Expand Tx Arsenal
September 1st 2003San Francisco - The topical immunomodulators imiquimod (Aldara), tacrolimus (Protopic), and pimecrolimus (Elidel) are proving to be extremely useful agents for the effective management of a number of skin conditions, Mark Lebwohl, M.D., said at the annual meeting of the American Academy of Dermatology.
Multiple Sets of Factors May Trigger AA
August 1st 2003Barcelona - The onset age of alopecia areata (AA) peaks in both the late teens and around 30 years, according to Andrew J. G. McDonagh, M.D., consultant dermatologist (U.K.-certified in dermatology), University of Sheffield's Royal Hallamshire Hospital.